Renal cell carcinoma induces prostaglandin E2 and T-helper type 2 cytokine production in peripheral blood mononuclear cells

Annals of Surgical Oncology

Volumn 10, Issue 4, 2003, Pages 455-462

  Smyth, Gordon P ^a   Stapleton, Philip P ^a,b   Barden, Catherine B ^a   Mestre, Juan R ^a   Freeman, Tracy A ^a   Duff, Michael D ^a   Maddali, Sirish ^a   Yan, Zhaoping ^a   Daly, John M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

COX 2 inhibition; Peripheral blood mononuclear cells; Prostaglandin E2; Renal cell carcinoma; Th2 cytokines

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2;

ARTICLE; CELL LINE; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOPHARMACOLOGY; KIDNEY CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH2 CELL; BIOSYNTHESIS; CELL CULTURE; CULTURE MEDIUM; IMMUNOLOGY; KIDNEY TUMOR; METABOLISM;

CARCINOMA, RENAL CELL; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; CYTOKINES; DINOPROSTONE; HUMANS; INTERLEUKIN-2; INTERLEUKIN-6; KIDNEY NEOPLASMS; RNA, MESSENGER; TH2 CELLS; TUMOR CELLS, CULTURED;

EID: 0042161469     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2003.06.036     Document Type: Article

References (43)

1. Landis S, Murray T, Bolden S. Cancer statistics, 1999. Cancer J Clin 1999;49:8-31.
2. Amato R. Chemotherapy for renal cell carcinoma. Semin Oncol 2000;27:177-86.
3. Evans R. Macrophage requirement for growth of a murine fibrosarcoma. Br J Cancer 1978;37:1086-9.
4. Leek R, Lewis C, Whitehouse R, Greenall M, Clarke J, Harris A. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast cancer. Cancer Res 1996;56:4625-9.
5. Bennett A. The production of prostanoids in human cancers and their implications for tumor progression. Prog Lipid Res 1986;25:539-42.
6. Goodwin J, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol 1983;3:295-315.
7. Oshima M, Dinchuk J, Kargman S. Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
8. Hull M, Booth J, Tisbury A, et al. Cyclooxygenase 2 is upregulated and localized to macrophages in the intestine of Min mice. Br J Cancer 1999;79:1399-405.
9. Eisengart C, Mestre J, Naama H, et al. Prostaglandins regulate melanoma-induced cytokine production in macrophages. Cell Immunol 2000;204:143-9.
10. Pellegrini P, Berghella A, Beato TD, Cicia S, Adorno D, Casciani C. Disregulation in Th1 and Th2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 1996;42:1-8.
11. Mosman T, Coffman R. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
12. DelPrete G, DeCarli M, Ricci M, Romagnani S. Helper activity for immunoglobulin synthesis of T helper type 1 (Th1) and Th2 human T cell clones: the help of Th 1 clones is limited by their cytolytic capacity. J Exp Med 1991;174:809-13.
13. Asselin-Paturel C, Echchakir H, Carayol G, et al. Quantitative analysis of Th1, Th2 and TGF-beta 1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer 1998;77:7-12.
14. Ren Z, Pang G, Clancy R, et al. Gastric carcinoma: T cell response and vascularity. Shift of the gastric T-cell response in gastric carcinoma. J Gastroenterol Hepatol 2001;16:142-8.
15. Snijdewint F, Kalinski P, Wierenga E, Bos J, Kapsenberg M. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 1993;150:5321-9.
16. Katamura K, Shintaku N, Yamauchi Y, et al. Prostaglandin E2 at priming of naive CD4+ T cells inhibits acquisition of ability to produce IFN-gamma and IL-2, but not IL-4 and IL-5. J Immunol 1995;155:4604-12.
17. Wu C, Wang K, McDyer J, Seder R. Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J Immunol 1998;161:2723-30.
18. Tineke C, Kraan V, Boeije L, Smeenk R, Wijdenes J, Aarden L. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995;181:775-9.
19. Hilkens G, Snijders A, Vermeulen H, Meide P, Wierenga E, Kapsenberg M. Accessory cell-derived IL-12 and prostaglandin E2 determine the IFN-gamma level of activated human CD4+ T cells. Ann N Y Acad Sci 1996;795:349-50.
20. Kuroda E, Sugiura T, Zeki K, Yoshida Y, Yamashita U. Sensitivity difference to the suppressive effect of prostaglandin E2 among mouse strains: a possible mechanism to polarize Th2 type response in BALB/c mice. J Immunol 2000;164:2386-95.
21. Oliver R, Nethersell A, Bottomley J. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal cell carcinoma. Br J Urol 1989;63:128-31.
22. Tykka H, Oravisto K, Lehtonen T, Sarna S, Tallberg T. Active specific immunotherapy of advanced renal-cell carcinoma. Eur Urol 1978;4:250-8.
23. Finke J. Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunother 1992;11:1-11.
24. Uzzo R, Rayman P, Kolenko V, et al. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappa B activation in T cells. J Clin Invest 1999;104:769-76.
25. Meischer S, Stoeck M, Qiao L, Barras C, Barrelet L, VonFliedner V. Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors. Cancer Res 1988;48:6992-8.
26. Alexander J, Kudoh S, Melsop K, et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 1993;53:1380-7.
27. Tsujii M, Bois RD. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
28. Tsujii M, Kawano S, Tsujii S, Sawaoka H, Hori M, Bois RD. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
29. Plescia O, Smith A, Grinwich K. Subversion of the immune system by tumor cells and the role of prostaglandins. Proc Natl Acad Sci U S A 1975;72:1848-51.
30. Bennett A, Charlier E, McDonald A, Simpson J, Stamford I, Zebro T. Prostaglandins and breast cancer. Lancet 1977;2:624-6.
31. Bennett A. The production of prostanoids in human cancers, and their implications for tumor progression. Prog Lipid Res 1986;25:539-42.
32. Subbaramaiah K, Zakim D, Weksler B, Dannenberg A. Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med 1997;216:201-10.
33. Rigas B, Goldman I, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993;122:518-23.
34. Tucker O, Dannenberg A, Yang E, et al. Cyclooxygenase 2 is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-90.
35. Chan G, Boyle J, Yang E, et al. Cyclooxygenase-2 is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-4.
36. Soslow R, Dannenberg A, Rush D, et al. COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer 2000;89:2637-45.
37. Kulkarni S, Rader J, Zhang F, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001;7:429-34.
38. Zeidler R, Csanady M, Gires O, Lang S, Schmitt B, Wollenberg B. Tumor cell-derived prostaglandin E2 inhibits monocyte function by interfering with CCR5 and Mac-1. FASEB J 2000;14:661-8.
39. Hsieh C, Macatonia S, Tripp C, Wolf S, O'Garra A, Murphy K. Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547-50.
40. Gately M, Wolitzky A, Quinn P, Chizzonite R. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 1992;143:127-42.
41. Mehrota P, Win D, Crim J, Mostowski H, Siegel J. Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol 1993;151:2444-52.
42. Coughlin C, Salhany K, Gee M, et al. Tumor cell responses to IFN-gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998;9:25-34.
43. Bellone G, Turletti A, Artusio E, et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 1999;155:537-47.